PAH Features

PAH Six-Minute Walk Test

Could a Mobile App Boost the Utility of the Six-Minute Walk Test in PAH?

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vascular proliferation and remodeling of the small pulmonary arteries that ultimately causes right heart failure and premature death. The predominant symptom of PAH is dyspnea on exertion, with a decrease in exercise capacity.1 A variety of methods are available for the objective assessment of…

Hagit Baris-Feldman

Israel Emerges as Global Powerhouse in Rare Disease Research

TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…

hemophilia types

Study Suggests sRAGE as a Potential Biomarker for Adult PAH

Researchers found that the plasma concentration of soluble receptor for advanced glycation end products (sRAGE) is a sensitive and accurate biomarker for adult pulmonary arterial hypertension (PAH). They concluded that sRAGE “has comparable diagnostic accuracy to the established heart failure biomarker [N-terminal prohormone of brain natriuretic peptide] and shows even better performance in the distinction…

Noah Greenspan

The Prognosis for Patients With PAH Is Improving, but Early Detection Is Key

NEW YORK, New York — Pulmonary arterial hypertension (PAH) is an extremely rare disease, affecting anywhere between 2.0 people per million in the United States to 7.6 per million in Scotland, according to a 2019 review article in European Respiratory Review. In fact, PAH is so rare, says Noah Greenspan, DPT, even many pulmonologists don’t know what to…

NORD t-shirts for sale

NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards

Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses. The virtual ceremony was hosted by John Whyte, MD, MPH, chief medical officer at WebMD, with commentary…

NORD banners

FDA, CDC Urge COVID-19 Vaccines for Rare Disease Patients on NORD Webinar

As the super-contagious Delta variant of COVID-19 sweeps across the globe, driving up infection rates as well as deaths, top US health officials are urging everyone 12 and older — including the country’s 30 million or so rare disease patients — to get vaccinated quickly. Some 185 million people have been infected, and nearly 4…

PHA Europe

PHA Europe Assists Pulmonary Hypertension Patients in 27 Countries

Before his life got turned upside down, Gerald Fischer was a top manager at one of Europe’s largest tour operators, traveling the world on behalf of leading Austrian celebrities while running his family’s thriving liquor business as a fifth-generation distiller. Everything changed in 1998, the year Fischer’s frail 3-year-old daughter Maleen was diagnosed with pulmonary…

Next post in Features